Prediction of recurrence after resection in hepatocellular carcinoma via whole liver deep learning on preoperative contrast-enhanced CT
This study aimed to develop a fully automated survival prediction (FASP) system that analyzes whole-liver regions from preoperative contrast-enhanced CT scans for predicting recurrence-free survival (RFS) after curative resection in Hepatocellular carcinoma (HCC). FASP comprised three consecutive components: automatic liver and tumor segmentation models, and a RFS prediction model, LiverSurv, all based on deep convolutional neural networks. FASP was compared against a clinical model leveraging clinical factors and three tumor-based methods using semantic, radiomic, or deep learning features. A total of 827 patients were included across the development, internal test, and external test sets. In the internal and external test sets, FASP achieved concordance indices (C-indices) of 0.646 (95% CI: 0.566, 0.725) and 0.786 (95% CI: 0.726, 0.846), respectively, outperforming the clinical model (both adjusted P<.05). Integrating clinical factors improved C-indices to 0.664 (95% CI: 0.591, 0.736) internally and 0.800 (95% CI: 0.750, 0.849) externally. FASP also surpassed the tumor-based models, which yielded C-indices ranging from 0.623 to 0.632 internally and 0.523 to 0.775 externally. Visualization analysis demonstrated that FASP captured prognostic information from both tumor and background liver regions. These findings suggest whole-liver-based deep learning provides a promising non-invasive approach to predict recurrence risk for HCC patients before surgery.
Authors
- Jingsong Li (ORCID: https://orcid.org/0000-0002-1064-637X)
- Jing Liu (ORCID: https://orcid.org/0000-0002-3311-0818)
- Chao‐Yuan Huang (ORCID: https://orcid.org/0000-0002-9322-6062)
- Tianshu Zhou (ORCID: https://orcid.org/0000-0002-5858-6353)
- Yu Tian (ORCID: https://orcid.org/0000-0002-6791-8217)
- Qi Zhang (ORCID: https://orcid.org/0000-0001-9916-8919)
- Weibin Wang (ORCID: https://orcid.org/0000-0002-8581-290X)
- Yingying Xu (ORCID: https://orcid.org/0000-0003-1217-0448)
- Peijun Hu (ORCID: https://orcid.org/0000-0002-5593-1553)
- Mu Zhou (ORCID: https://orcid.org/0000-0001-5072-5630)
- Yangyang Wang (ORCID: https://orcid.org/0009-0006-9428-2433)
- Yiwei Gao
Institutions
- Rutgers, The State University of New Jersey (US)
- Zhejiang Cancer Hospital (CN)
- Environmental and Occupational Health Sciences Institute (US)
- Zhejiang Lab (CN)
- Shanghai Clinical Research Center (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Scientific Reports
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1038/s41598-025-26933-x
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Major Research Plan
- Fundamental Research Funds for the Central Universities
- Natural Science Foundation of Zhejiang Province